GlassScriptPhysician profile
David L Zumerchik
NPI 1669480950
$7,201.22
in general payments reported to CMS, 2019-2025
46 companies · $1,200 in 2025
The $1,200 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $968 · 2021: $1,319 · 2022: $1,048 · 2023: $813 · 2024: $1,196 · 2025: $1,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,010 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,010.42 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $860.37 | 2019-2025 | Xtandi |
| Abbvie INC. | $734.62 | 2019-2025 | Lupron Depot |
| Bayer Healthcare Pharmaceuticals INC. | $631.40 | 2019-2025 | |
| Teleflex LLC | $505.17 | 2021-2025 | Barrigel, Urolift |
| Janssen Biotech, INC. | $438.25 | 2019-2025 | Erleada |
| Sumitomo Pharma America, INC. | $338.58 | 2023-2025 | Orgovyx, Gemtesa |
| Blue Earth Diagnostics | $325.21 | 2020-2025 | Posluma |
| Dendreon Pharmaceuticals LLC | $291.37 | 2019-2024 | Provenge |
| Pfizer INC. | $274.15 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $247.02 | 2021-2025 | Keytruda, Lynparza |
| Boston Scientific Corporation | $193.19 | 2020-2025 | Ams 700, Lithovue |
| Myriad Genetic Laboratories, INC. | $182.39 | 2021-2025 | Prolaris |
| Olympus America INC. | $169.27 | 2022-2025 | Itind System |
| Endo Pharmaceuticals INC. | $164.54 | 2019-2023 | Xiaflex, Aveed, Edex |
| Progenics Pharmaceuticals, INC. | $158.29 | 2022-2025 | Pylarify |
Show all 45 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$122,060.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Zumerchik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.